Comparison of resolute zotarolimus-eluting stents and sirolimus-eluting stents in patients with de novo long coronary artery lesions a randomized LONG-DES IV trial

Jung Min Ahn, Duk Woo Park, Young Hak Kim, Haegeun Song, Young Rak Cho, Won Jang Kim, Jong Young Lee, Soo Jin Kang, Seung Whan Lee, Cheol Whan Lee, Seong Wook Park, Sung Cheol Yun, Seungbong Han, Sung Yun Lee, Bong Ki Lee, Jang Hyun Cho, Tae Hyun Yang, Nae Hee Lee, Joo Young Yang, Jong Seon ParkWon Yong Shin, Moo Hyun Kim, Jang Ho Bae, Myeong Kon Kim, Junghan Yoon, Seung Jung Park

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background: Procedural and clinical outcomes still remain unfavorable for patients with long coronary lesions who undergo stent-based coronary interventions. Therefore, we compared the relative efficacy and safety of resolute zotarolimus-eluting stents (R-ZES) and sirolimus-eluting stents (SES) for patients with de novo long coronary lesions. Methods and Results: This randomized, multicenter, prospective trial, called the Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-IV (LONG-DES IV) trial, compared long R-ZES and SES in 500 patients with long (≥25 mm) native coronary lesions. The primary end point of the trial was in-segment late luminal loss at 9-month angiographic follow-up. The baseline characteristics were not different between R-ZES and SES groups, including lesion lengths (32.4±13.5 mm versus 31.0±13.5 mm, P=0.27). At 9-month angiographic follow-up, the R-ZES was noninferior to the SES with respect to in-segment late luminal loss, the primary study end point (0.14±0.38 mm versus 0.12±0.43 mm, P for noninferiority=0.03, P for superiority=0.68). In addition, in-stent late luminal loss (0.26±0.36 mm versus 0.24±0.42 mm, P=0.78) and the rates of in-segment (5.2% versus 7.2%, P=0.44) and in-stent (4.0% versus 6.0%, P=0.41) binary restenosis were not significantly different between the 2 groups. There were no significant between-group differences in the rate of adverse clinical events (death, myocardial infarction, stent thrombosis, target-lesion revascularization, and composite outcomes). Conclusions: For patients with de novo long coronary artery disease, R-ZES implantation showed noninferior angiographic outcomes as compared with SES implantation.

Original languageEnglish
Pages (from-to)633-640
Number of pages8
JournalCirculation: Cardiovascular Interventions
Volume5
Issue number5
DOIs
Publication statusPublished - 2012 Oct 1

Fingerprint

Sirolimus
Stents
Coronary Vessels
zotarolimus
Drug-Eluting Stents
Multicenter Studies
Coronary Artery Disease
Thrombosis
Myocardial Infarction

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Ahn, Jung Min ; Park, Duk Woo ; Kim, Young Hak ; Song, Haegeun ; Cho, Young Rak ; Kim, Won Jang ; Lee, Jong Young ; Kang, Soo Jin ; Lee, Seung Whan ; Lee, Cheol Whan ; Park, Seong Wook ; Yun, Sung Cheol ; Han, Seungbong ; Lee, Sung Yun ; Lee, Bong Ki ; Cho, Jang Hyun ; Yang, Tae Hyun ; Lee, Nae Hee ; Yang, Joo Young ; Park, Jong Seon ; Shin, Won Yong ; Kim, Moo Hyun ; Bae, Jang Ho ; Kim, Myeong Kon ; Yoon, Junghan ; Park, Seung Jung. / Comparison of resolute zotarolimus-eluting stents and sirolimus-eluting stents in patients with de novo long coronary artery lesions a randomized LONG-DES IV trial. In: Circulation: Cardiovascular Interventions. 2012 ; Vol. 5, No. 5. pp. 633-640.
@article{bef63c5da37147029cc504b1cb806724,
title = "Comparison of resolute zotarolimus-eluting stents and sirolimus-eluting stents in patients with de novo long coronary artery lesions a randomized LONG-DES IV trial",
abstract = "Background: Procedural and clinical outcomes still remain unfavorable for patients with long coronary lesions who undergo stent-based coronary interventions. Therefore, we compared the relative efficacy and safety of resolute zotarolimus-eluting stents (R-ZES) and sirolimus-eluting stents (SES) for patients with de novo long coronary lesions. Methods and Results: This randomized, multicenter, prospective trial, called the Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-IV (LONG-DES IV) trial, compared long R-ZES and SES in 500 patients with long (≥25 mm) native coronary lesions. The primary end point of the trial was in-segment late luminal loss at 9-month angiographic follow-up. The baseline characteristics were not different between R-ZES and SES groups, including lesion lengths (32.4±13.5 mm versus 31.0±13.5 mm, P=0.27). At 9-month angiographic follow-up, the R-ZES was noninferior to the SES with respect to in-segment late luminal loss, the primary study end point (0.14±0.38 mm versus 0.12±0.43 mm, P for noninferiority=0.03, P for superiority=0.68). In addition, in-stent late luminal loss (0.26±0.36 mm versus 0.24±0.42 mm, P=0.78) and the rates of in-segment (5.2{\%} versus 7.2{\%}, P=0.44) and in-stent (4.0{\%} versus 6.0{\%}, P=0.41) binary restenosis were not significantly different between the 2 groups. There were no significant between-group differences in the rate of adverse clinical events (death, myocardial infarction, stent thrombosis, target-lesion revascularization, and composite outcomes). Conclusions: For patients with de novo long coronary artery disease, R-ZES implantation showed noninferior angiographic outcomes as compared with SES implantation.",
author = "Ahn, {Jung Min} and Park, {Duk Woo} and Kim, {Young Hak} and Haegeun Song and Cho, {Young Rak} and Kim, {Won Jang} and Lee, {Jong Young} and Kang, {Soo Jin} and Lee, {Seung Whan} and Lee, {Cheol Whan} and Park, {Seong Wook} and Yun, {Sung Cheol} and Seungbong Han and Lee, {Sung Yun} and Lee, {Bong Ki} and Cho, {Jang Hyun} and Yang, {Tae Hyun} and Lee, {Nae Hee} and Yang, {Joo Young} and Park, {Jong Seon} and Shin, {Won Yong} and Kim, {Moo Hyun} and Bae, {Jang Ho} and Kim, {Myeong Kon} and Junghan Yoon and Park, {Seung Jung}",
year = "2012",
month = "10",
day = "1",
doi = "10.1161/CIRCINTERVENTIONS.111.965673",
language = "English",
volume = "5",
pages = "633--640",
journal = "Circulation: Cardiovascular Interventions",
issn = "1941-7640",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

Ahn, JM, Park, DW, Kim, YH, Song, H, Cho, YR, Kim, WJ, Lee, JY, Kang, SJ, Lee, SW, Lee, CW, Park, SW, Yun, SC, Han, S, Lee, SY, Lee, BK, Cho, JH, Yang, TH, Lee, NH, Yang, JY, Park, JS, Shin, WY, Kim, MH, Bae, JH, Kim, MK, Yoon, J & Park, SJ 2012, 'Comparison of resolute zotarolimus-eluting stents and sirolimus-eluting stents in patients with de novo long coronary artery lesions a randomized LONG-DES IV trial', Circulation: Cardiovascular Interventions, vol. 5, no. 5, pp. 633-640. https://doi.org/10.1161/CIRCINTERVENTIONS.111.965673

Comparison of resolute zotarolimus-eluting stents and sirolimus-eluting stents in patients with de novo long coronary artery lesions a randomized LONG-DES IV trial. / Ahn, Jung Min; Park, Duk Woo; Kim, Young Hak; Song, Haegeun; Cho, Young Rak; Kim, Won Jang; Lee, Jong Young; Kang, Soo Jin; Lee, Seung Whan; Lee, Cheol Whan; Park, Seong Wook; Yun, Sung Cheol; Han, Seungbong; Lee, Sung Yun; Lee, Bong Ki; Cho, Jang Hyun; Yang, Tae Hyun; Lee, Nae Hee; Yang, Joo Young; Park, Jong Seon; Shin, Won Yong; Kim, Moo Hyun; Bae, Jang Ho; Kim, Myeong Kon; Yoon, Junghan; Park, Seung Jung.

In: Circulation: Cardiovascular Interventions, Vol. 5, No. 5, 01.10.2012, p. 633-640.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparison of resolute zotarolimus-eluting stents and sirolimus-eluting stents in patients with de novo long coronary artery lesions a randomized LONG-DES IV trial

AU - Ahn, Jung Min

AU - Park, Duk Woo

AU - Kim, Young Hak

AU - Song, Haegeun

AU - Cho, Young Rak

AU - Kim, Won Jang

AU - Lee, Jong Young

AU - Kang, Soo Jin

AU - Lee, Seung Whan

AU - Lee, Cheol Whan

AU - Park, Seong Wook

AU - Yun, Sung Cheol

AU - Han, Seungbong

AU - Lee, Sung Yun

AU - Lee, Bong Ki

AU - Cho, Jang Hyun

AU - Yang, Tae Hyun

AU - Lee, Nae Hee

AU - Yang, Joo Young

AU - Park, Jong Seon

AU - Shin, Won Yong

AU - Kim, Moo Hyun

AU - Bae, Jang Ho

AU - Kim, Myeong Kon

AU - Yoon, Junghan

AU - Park, Seung Jung

PY - 2012/10/1

Y1 - 2012/10/1

N2 - Background: Procedural and clinical outcomes still remain unfavorable for patients with long coronary lesions who undergo stent-based coronary interventions. Therefore, we compared the relative efficacy and safety of resolute zotarolimus-eluting stents (R-ZES) and sirolimus-eluting stents (SES) for patients with de novo long coronary lesions. Methods and Results: This randomized, multicenter, prospective trial, called the Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-IV (LONG-DES IV) trial, compared long R-ZES and SES in 500 patients with long (≥25 mm) native coronary lesions. The primary end point of the trial was in-segment late luminal loss at 9-month angiographic follow-up. The baseline characteristics were not different between R-ZES and SES groups, including lesion lengths (32.4±13.5 mm versus 31.0±13.5 mm, P=0.27). At 9-month angiographic follow-up, the R-ZES was noninferior to the SES with respect to in-segment late luminal loss, the primary study end point (0.14±0.38 mm versus 0.12±0.43 mm, P for noninferiority=0.03, P for superiority=0.68). In addition, in-stent late luminal loss (0.26±0.36 mm versus 0.24±0.42 mm, P=0.78) and the rates of in-segment (5.2% versus 7.2%, P=0.44) and in-stent (4.0% versus 6.0%, P=0.41) binary restenosis were not significantly different between the 2 groups. There were no significant between-group differences in the rate of adverse clinical events (death, myocardial infarction, stent thrombosis, target-lesion revascularization, and composite outcomes). Conclusions: For patients with de novo long coronary artery disease, R-ZES implantation showed noninferior angiographic outcomes as compared with SES implantation.

AB - Background: Procedural and clinical outcomes still remain unfavorable for patients with long coronary lesions who undergo stent-based coronary interventions. Therefore, we compared the relative efficacy and safety of resolute zotarolimus-eluting stents (R-ZES) and sirolimus-eluting stents (SES) for patients with de novo long coronary lesions. Methods and Results: This randomized, multicenter, prospective trial, called the Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-IV (LONG-DES IV) trial, compared long R-ZES and SES in 500 patients with long (≥25 mm) native coronary lesions. The primary end point of the trial was in-segment late luminal loss at 9-month angiographic follow-up. The baseline characteristics were not different between R-ZES and SES groups, including lesion lengths (32.4±13.5 mm versus 31.0±13.5 mm, P=0.27). At 9-month angiographic follow-up, the R-ZES was noninferior to the SES with respect to in-segment late luminal loss, the primary study end point (0.14±0.38 mm versus 0.12±0.43 mm, P for noninferiority=0.03, P for superiority=0.68). In addition, in-stent late luminal loss (0.26±0.36 mm versus 0.24±0.42 mm, P=0.78) and the rates of in-segment (5.2% versus 7.2%, P=0.44) and in-stent (4.0% versus 6.0%, P=0.41) binary restenosis were not significantly different between the 2 groups. There were no significant between-group differences in the rate of adverse clinical events (death, myocardial infarction, stent thrombosis, target-lesion revascularization, and composite outcomes). Conclusions: For patients with de novo long coronary artery disease, R-ZES implantation showed noninferior angiographic outcomes as compared with SES implantation.

UR - http://www.scopus.com/inward/record.url?scp=84868641244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868641244&partnerID=8YFLogxK

U2 - 10.1161/CIRCINTERVENTIONS.111.965673

DO - 10.1161/CIRCINTERVENTIONS.111.965673

M3 - Article

C2 - 23048051

AN - SCOPUS:84868641244

VL - 5

SP - 633

EP - 640

JO - Circulation: Cardiovascular Interventions

JF - Circulation: Cardiovascular Interventions

SN - 1941-7640

IS - 5

ER -